This study aimed to evaluate whether the novel compound 1-PPA, that we have recently demonstrated to inhibit PAR2 activation [27] and to markedly reduce the inflammatory response [26], could be an effective compound to reduce neuroinflammation in PD. Here, F2RL1 is linked to Parkinson disease.